Last reviewed 2026-05-21 · How we verify

PF-02921367 (pf-02921367)

Pfizer Inc. · FDA-approved active Quality 3/100

PF-02921367 (generic name: pf-02921367) is a drug developed by Pfizer Inc.. It is currently FDA-approved.

At a glance

Generic name	pf-02921367
Sponsor	Pfizer Inc.
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-02921367 CI brief — competitive landscape report
PF-02921367 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about PF-02921367

What is PF-02921367?

PF-02921367 (pf-02921367) is a pharmaceutical drug developed by Pfizer Inc..

Who makes PF-02921367?

PF-02921367 is developed and marketed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of PF-02921367?

pf-02921367 is the generic (nonproprietary) name of PF-02921367.

What development phase is PF-02921367 in?

PF-02921367 is FDA-approved (marketed).

Manufacturer: Pfizer Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing